Association of visceral adipose tissue with albuminuria and interaction between visceral adiposity and diabetes on albuminuria.
Albuminuria
Diabetes
Interaction
Visceral fat
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
05
01
2024
accepted:
03
03
2024
medline:
1
4
2024
pubmed:
1
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
To explore the correlation between visceral adipose tissue and albuminuria, and whether there is interaction between visceral adipose tissue and diabetes on albuminuria. The study subjects were adult subjects (age ≥ 18 years) from the National Health and Nutrition Examination Surveys (NHANES) database of the USA in 2017-2018. Visceral fat area (VFA) was measured by dual-energy X-ray absorptiometry (DXA). Subjects were divided into three groups according to VFA: low (VFA 0-60cm Data pertaining to 2965 participants (2706 without albuminuria) were included in the analysis. High VFA is an independent risk factor for albuminuria (OR 1.367, 95% CI 1.023-1.827). In the low-VFA group, there is no significant association between diabetes and albuminuria (OR 1.415, 95% CI 0.145-13.849). In the medium-VFA group, diabetes is an independent risk factor for albuminuria (OR 2.217, 95% CI 1.095-4.488). In the high-VFA group, diabetes is also an independent risk factor for albuminuria (OR 5.150, 95% CI 3.150-8.421). There is an additive interaction between high VFA (VFA ≥ 120 cm High VFA may represent an independent risk factor for albuminuria. The amount of visceral fat may affect the effect of diabetes on albuminuria. The higher the visceral fat, the stronger the correlation between diabetes and albuminuria should be present. We suppose an additive interaction between VFA and diabetes on the effect of albuminuria.
Identifiants
pubmed: 38558152
doi: 10.1007/s00592-024-02271-8
pii: 10.1007/s00592-024-02271-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Viberti GC, Pickup JC, Jarrett RJ, Keen H (1979) Effect of control of blood glucose on urinary excretion of albumin and beta2 microglobulin in insulin-dependent diabetes. N Engl J Med 300(12):638–641
pubmed: 84336
doi: 10.1056/NEJM197903223001202
Parving HH (1996) Initiation and progression of diabetic nephropathy. N Engl J Med 335(22):1682–1683
pubmed: 8929369
doi: 10.1056/NEJM199611283352212
Després JP, Lemieux S, Lamarche B et al (1995) The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes Relat Metab Disord 19(Suppl 1):S76-86
pubmed: 7550542
Pulgaron ER, Delamater AM (2014) Obesity and type 2 diabetes in children: epidemiology and treatment. Curr Diab Rep 14(8):508
pubmed: 24919749
pmcid: 4099943
doi: 10.1007/s11892-014-0508-y
Cases A, Coll E (2005) Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 99:S87-93
doi: 10.1111/j.1523-1755.2005.09916.x
Gyebi L, Soltani Z, Reisin E (2012) Lipid nephrotoxicity: new concept for an old disease. Curr Hypertens Rep 14(2):177–181
pubmed: 22290079
doi: 10.1007/s11906-012-0250-2
Foster MC, Hwang SJ, Massaro JM et al (2011) Association of subcutaneous and visceral adiposity with albuminuria: the Framingham Heart Study. Obesity (Silver Spring) 19(6):1284–1289
pubmed: 21183930
doi: 10.1038/oby.2010.308
Hanai K, Babazono T, Nyumura I et al (2010) Involvement of visceral fat in the pathogenesis of albuminuria in patients with type 2 diabetes with early stage of nephropathy. Clin Exp Nephrol 14(2):132–136
pubmed: 20091203
doi: 10.1007/s10157-009-0245-8
Kim SR, Yoo JH, Song HC et al (2011) Relationship of visceral and subcutaneous adiposity with renal function in people with type 2 diabetes mellitus. Nephrol Dial Transplant 26(11):3550–3555
pubmed: 21030458
doi: 10.1093/ndt/gfq634
Preis SR, Massaro JM, Robins SJ et al (2010) Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring) 18(11):2191–2198
pubmed: 20339361
doi: 10.1038/oby.2010.59
Du T, Yuan G, Zhang M et al (2014) Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol 13:146
pubmed: 25326814
pmcid: 4209231
doi: 10.1186/s12933-014-0146-3
Britton KA, Massaro JM, Murabito JM et al (2013) Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol 62(10):921–925
pubmed: 23850922
pmcid: 4142485
doi: 10.1016/j.jacc.2013.06.027
Stevens PE, Levin A (2013) Kidney disease: improving global outcomes chronic kidney disease guideline development work group members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Int Med. 158(11):825–830
pubmed: 23732715
doi: 10.7326/0003-4819-158-11-201306040-00007
American Diabetes Association Professional Practice Committee (2022) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1):17–38
doi: 10.2337/dc22-S002
Knol MJ, Vander Weele TJ, Groenwold RH et al (2011) Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol 26(6):433–438
pubmed: 21344323
pmcid: 3115067
doi: 10.1007/s10654-011-9554-9
Yang X, Zhao H, Sui Y et al (2009) Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 58(7):1518–1525
pubmed: 19401427
pmcid: 2699870
doi: 10.2337/db09-0105
Bouchi R, Ohara N, Asakawa M et al (2016) Is visceral adiposity a modifier for the impact of blood pressure on arterial stiffness and albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 15:10
pubmed: 26790628
pmcid: 4721003
doi: 10.1186/s12933-016-0335-3
Kramer H, Shoham D, McClure LA et al (2011) Association of waist circumference and body mass index with all-cause mortality in CKD: the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 58(2):177–185
pubmed: 21601327
pmcid: 3144322
doi: 10.1053/j.ajkd.2011.02.390
Postorino M, Marino C, Tripepi G, Zoccali C (2009) CREDIT (Calabria registry of dialysis and transplantation) working group. Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol 53(15):1265–1272
pubmed: 19358939
doi: 10.1016/j.jacc.2008.12.040
Kovesdy CP, Czira ME, Rudas A et al (2010) Body mass index, waist circumference and mortality in kidney transplant recipients. Am J Transplant 10(12):2644–2651
pubmed: 21087417
doi: 10.1111/j.1600-6143.2010.03330.x
Neeland IJ, Poirier P, Després JP (2018) Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 137(13):1391–1406
pubmed: 29581366
pmcid: 5875734
doi: 10.1161/CIRCULATIONAHA.117.029617
Katzmarzyk PT, Heymsfield SB, Bouchard C (2013) Clinical utility of visceral adipose tissue for the identification of cardiometabolic risk in white and African American adults. Am J Clin Nutr 97(3):480–486
pubmed: 23364010
pmcid: 3578400
doi: 10.3945/ajcn.112.047787
Madero M, Katz R, Murphy R et al (2017) Comparison between different measures of body fat with kidney function decline and incident CKD. Clin J Am Soc Nephrol 12(6):893–903
pubmed: 28522656
pmcid: 5460706
doi: 10.2215/CJN.07010716
Sun K, Lin D, Li F et al (2019) Visceral adiposity index is associated with increased urinary albumin excretion: a population-based study. Clin Nutr 38(3):1332–1338
pubmed: 29895473
doi: 10.1016/j.clnu.2018.05.025
Wen J, Yuan H (2020) Independent association between the visceral adiposity index and microalbuminuria in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev 36(1):e3198
pubmed: 31228226
doi: 10.1002/dmrr.3198
Zhou C, Zhang Y, Yang S et al (2023) Associations between visceral adiposity index and incident nephropathy outcomes in diabetic patients: insights from the ACCORD trial. Diabetes Metab Res Rev 39(3):e3602
pubmed: 36546623
doi: 10.1002/dmrr.3602
Tamba S, Nakatsuji H, Kishida K et al (2010) Relationship between visceral fat accumulation and urinary albumin-creatinine ratio in middle-aged Japanese men. Atherosclerosis 211(2):601–605
pubmed: 20363472
doi: 10.1016/j.atherosclerosis.2010.02.037
Ghigliotti G, Barisione C, Garibaldi S et al (2014) Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation 37(4):1337–1353
pubmed: 24823865
doi: 10.1007/s10753-014-9914-1
Sharma K, Considine RV, Michael B et al (1997) Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 51(6):1980–1985
pubmed: 9186891
doi: 10.1038/ki.1997.269
Sharma K, Ramachandrarao S, Qiu G et al (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118(5):1645–1656
pubmed: 18431508
pmcid: 2323186
Axelsson J, Bergsten A, Qureshi AR et al (2006) Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 69(3):596–604
pubmed: 16395259
doi: 10.1038/sj.ki.5000089
Malyszko J, Malyszko JS, Mysliwiec M (2009) Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc 41(1):150–153
pubmed: 19249500
doi: 10.1016/j.transproceed.2008.10.086
Song HK, Lee MH, Kim BK et al (2008) Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 295(5):F1485–F1494
pubmed: 18768589
doi: 10.1152/ajprenal.90231.2008
Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y (2003) Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 46(11):1483–1488
pubmed: 14534780
doi: 10.1007/s00125-003-1221-6
Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF (1996) Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 7(5):661–666
pubmed: 8738799
doi: 10.1681/ASN.V75661
Imig JD, Ryan MJ (2013) Immune and inflammatory role in renal disease. Compr Physiol 3(2):957–976
pubmed: 23720336
pmcid: 3803162
doi: 10.1002/cphy.c120028
Kurozumi A, Okada Y, Arao T, Tanaka Y (2016) Excess visceral adipose tissue worsens the vascular endothelial function in patients with type 2 diabetes mellitus. Intern Med 55(21):3091–3095
pubmed: 27803400
pmcid: 5140855
doi: 10.2169/internalmedicine.55.6940
Kim SH, Després JP, Koh KK (2016) Obesity and cardiovascular disease: friend or foe. Eur Heart J 37(48):3560–3568
pubmed: 26685971
doi: 10.1093/eurheartj/ehv509
Wu CC, Liou HH, Su PF et al (2011) Abdominal obesity is the most significant metabolic syndrome component predictive of cardiovascular events in chronic hemodialysis patients. Nephrol Dial Transplant 26(11):3689–3695
pubmed: 21357211
doi: 10.1093/ndt/gfr057
Mathew AV, Okada S, Sharma K (2011) Obesity related kidney disease. Curr Diabetes Rev 7(1):41–49
pubmed: 21067508
doi: 10.2174/157339911794273928
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME (2015) Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 116(6):991–1006
pubmed: 25767285
pmcid: 4363087
doi: 10.1161/CIRCRESAHA.116.305697
Engeli S, Sharma AM (2001) The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med (Berl) 79(1):21–29
pubmed: 11327100
doi: 10.1007/s001090000144
de Paula RB, da Silva AA, Hall JE (2004) Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 43(1):41–47
pubmed: 14638627
doi: 10.1161/01.HYP.0000105624.68174.00
Fujioka H, Koike T, Imamura T et al (2023) Prognostic impact of renal sinus fat accumulation in patients with chronic kidney disease. Clin Exp Nephrol 27(7):613–621
pubmed: 37095344
doi: 10.1007/s10157-023-02350-0
Hall ME, do Carmo JM, da Silva AA et al (2014) Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Disease 7:75–88
doi: 10.2147/IJNRD.S39739
Choi JW, Oh IH, Lee CH, Park JS (2017) Effect of synergistic interaction between abnormal adiposity-related metabolism and prediabetes on microalbuminuria in the general population. PLoS ONE 12(7):e0180924
pubmed: 28715448
pmcid: 5513435
doi: 10.1371/journal.pone.0180924
Reinhardt M, Piaggi P, DeMers B, Trinidad C, Krakoff J (2017) Cross calibration of two dual-energy X-ray densitometers and comparison of visceral adipose tissue measurements by iDXA and MRI. Obesity (Silver Spring) 25(2):332–337
pubmed: 28000375
doi: 10.1002/oby.21722
Sneed NM, Morrison SA (2021) Body composition methods in adults with type 2 diabetes or at risk for T2D: a clinical review. Curr Diabetes Rep 21(5):14
doi: 10.1007/s11892-021-01381-9